Mechanism and Potential Therapy in Ameloblastoma: Akt Signaling Pathway

Abstract

BACKGROUND: Ameloblastoma is the most common benign aggressive tumor. They are more prevalent in the mandible than in the maxilla, mostly observed on the posterior of the jaw. Ameloblastoma can arise at any age, however it most usually affect patients between the ages of 20 and 40. Numerous efforts have been made to develop molecular targeted therapies to treat cancers, such as Akt inhibitors. However, these drugs have not been tested for treating ameloblastoma yet, since underlying molecular factors have yet to be identified. This study was carried out to delineate possible molecular mechanisms related to the Akt signaling pathway in ameloblastoma and potential drugs for ameloblastoma treatment. CONTENT: Akt signaling pathway in ameloblastoma has been implicated in the formation and progression of tumors. Akt signaling is involved in various cellular mechanisms, such as cell cycle, apoptosis, and cytoskeletal rearrangement, which includes Phosphatidyl Inositol 3 Kinase (PI3K)-Akt signaling, Akt-Nuclear Factor (NF)-κB signaling, Akt-Mammalian Target of Rapamycin (mTOR) signaling, Akt-B-cell Lymphoma (Bcl)-2 Family signaling, Akt-Survivin signaling. Potential ways of treatments using chemical compounds and micro RNA (miRNA), and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) were explored as well.SUMMARY: The present review highlights various Akt signaling involved in ameloblastoma and its potential pathways for treatments, while the gold standard of ameloblastoma treatment is still surgery to remove the tumor, there are many potential agents through various means of inhibition for ameloblastoma. Therefore, understanding the underlying signaling on ameloblastoma is necessary to induce inhibition on ameloblastoma. More research in potential ways to inhibit Akt signaling in ameloblastoma will lead to a better management of ameloblastoma in the future. KEYWORDS: ameloblastoma, Akt, PI3K, NFkB, mTOR, Bcl-2, miRNA, CRISPR

Viability, Migration Rate, and mRNA Expression of GLUT5, GLUT7, GLUT11 in WiDr Colorectal Cancer Cell Line

“…(11,12) PIK3CA mutations can increase proliferation and glycolysis processes both in normal and low glucose conditions, while p53 gene mutations can increase metastasis in colorectal cancer. (13)(14)(15) There is a limited number of studies regarding the effect of fructose or the combination of fructose-glucose on CRC and its effect on GLUT, especially GLUT5, GLUT7, and GLUT11, so this study was conducted to evaluate how much fructose and the combination of fructose-glucose play a role in the growth, migration, and expression of fructose transporters in CRC.…”

Análise da expressão imuno-histoquímica de PTEN, mTOR e NFkB em ameloblastomas

“…Outra proteína ativada pela via do NFkB é Ciclo-oxigenase 2 (COX2), presente nas células estromais do ameloblastoma (Hadi et al, 2022), sendo sua expressão correlacionada a expressão de -catenina que também regula positivamente a secreção de MMPs que influenciam na proliferação e invasividade dos ameloblastomas (Cecim et al, 2014). A ativação de NFkB está sempre presente no câncer (Figura 2.7), aumentando a proliferação e sobrevivência das células neoplásicas, promovendo alterações genéticas e epigenéticas, alterações metabólicas celulares, transição epitélio-mesenquimal, invasão, angiogênese, metástase, resistência a terapia e a supressão da imunidade antitumoral (Taniguchi;Karin, 2018).…”